The VINON-LOCA test facility: exploring the LOCA phenomenology through an out-of-pile thermal sequence on irradiated pressurized fuel rod

Since the out-of-pile semi-integral tests performed at Studsvik in 2011 for the NRC [1] and the Halden Loss-Of-Coolant Accident (LOCA) test series IFA-650 [2], a major safety interest has raised for Fuel Fragmentation, Relocation and Dispersal (FFRD) during a LOCA sequence. In addition to the characteristics of the fuel ejected from the rod after the clad failure, the fuel behaviour before the clad failure is still to be investigated, especially its fragmentation and its possible relocation within the rod during the clad ballooning phase. Furthermore, the chronology and the sequencing of these phenomena is of particular interest. For this purpose, the VINON-LOCA program, lying in the framework of a trilateral agreement between EDF, Framatome and CEA, is aimed at performing Out-Of-Pile heating tests on irradiated repressurized fuel rods, reproducing a typical Loss Of Coolant Accident thermal sequence. The VINON-LOCA experimental set-up is located in the so-called VERDON lab of the LECA-STAR hot cell complex. This lab was dedicated to the VERDON-ISTP program [3]. The VINON-LOCA set-up is thus largely instrumented for addressing not only these FFRD topics, but also Fission Gas Release (FGR), combining both online measurement (gamma stations, gamma camera, acoustic sensor, pressure, temperatures, flow meters, microGC…), and preand post-test characterization (gamma scanning, tomography, metrology, fuel fragments weighing and sieving, gas analyses…). An extensive and substantial qualification campaign has been performed to validate the furnace design regarding the desired test conditions, and to qualify the instrumentation. Following some preliminary modelling and calculations, it has included tests on an out-of-cell twin mockup and tests on dummy inactive rods in the hot cell. This allowed achieving successfully the first experimental qualification test of the program end of 2019 on an irradiated UO2 fuel rodlet. A second irradiated experiment is planned with increased instrumentation capabilities, notably a 2D gamma camera for online fuel motion detection

Frontiers in Multiscale Modeling of Photoreceptor Proteins

This perspective article highlights the challenges in the theoretical description of photoreceptor proteins using multiscale modeling, as discussed at the CECAM workshop in Tel Aviv, Israel. The participants have identified grand challenges and discussed the development of new tools to address them. Recent progress in understanding representative proteins such as green fluorescent protein, photoactive yellow protein, phytochrome, and rhodopsin is presented, along with methodological developments

Frontiers in Multiscale Modeling of Photoreceptor Proteins

This perspective article highlights the challenges in the theoretical description of photoreceptor proteins using multiscale modeling, as discussed at the CECAM workshop in Tel Aviv, Israel. The participants have identified grand challenges and discussed the development of new tools to address them. Recent progress in understanding representative proteins such as green fluorescent protein, photoactive yellow protein, phytochrome, and rhodopsin is presented, along with methodological developments

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

IF 7.191 (2017)International audienceBACKGROUND:Previous studies showed that high and low body mass index (BMI) was associated with worse prognosis in early-stage colorectal cancer (CRC), and low BMI was associated with worse prognosis in metastatic CRC (mCRC). We aimed to assess efficacy outcomes according to BMI.PATIENTS AND METHODS:A pooled analysis of individual data from 2085 patients enrolled in eight FFCD first-line mCRC trials from 1991 to 2013 was performed. Comparisons were made according to the BMI cut-off: Obese (BMI ≥30), overweight patients (BMI ≥ 25), normal BMI patients (BMI: 18.5-24) and thin patients (BMI <18.5). Interaction tests were performed between BMI effect and sex, age and the addition of antiangiogenics to chemotherapy.RESULTS:The rate of BMI ≥25 patients was 41.5%, ranging from 37.6% (1991-1999 period) to 41.5% (2000-2006 period) and 44.8% (2007-2013 period). Comparison of overweight patients versus normal BMI range patients revealed a significant improvement of median overall survival (OS) (18.5 versus 16.3 months, HR = 0.88 [0.80-0.98] p = 0.02) and objective response rate (ORR) (42% versus 36% OR = 1.23 [1.01-1.50] p = 0.04) but a comparable median progression-free survival (PFS) (7.8 versus 7.2 months, HR = 0.96 [0.87-1.05] p = 0.35). Subgroup analyses revealed that overweight was significantly associated with better OS in men. OS and PFS were significantly shorter in thin patients.CONCLUSION:Overweight patients had a prolonged OS compared with normal weight patients with mCRC. The association of overweight with better OS was only observed in men. The pejorative prognosis of BMI <18.5 was confirmed.Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserve